Anticancer potential of some imidazole and fused imidazole derivatives: exploring the mechanism via epidermal growth factor receptor (EGFR) inhibition. Issue 8 (8th July 2020)

• Record Type: Journal Article
• Authors: Kalra, Sourav; Joshi, Gaurav; Kumar, Manvendra; Arora, Sahil; Kaur, Harsimrat; Singh, Sandeep; Munshi, Anjana; Kumar, Raj
• Is Part Of: RSC medicinal chemistry. Volume 11:Issue 8(2020)
• Page Start: 923
• Page End: 939
• Publication Date: 2020-07-08
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1039/d0md00146e
• Languages: English
• ISSNs: 2632-8682

Abstract

Abstract : Imidazole-based epidermal growth factor receptor (EGFR) inhibitors were computationally designed and synthesized. Abstract : Imidazole-based epidermal growth factor receptor (EGFR) inhibitors were computationally designed and synthesized. All the compounds were assessed for their anti-proliferative activity against five cancer cell lines, viz., MDA-MB-231 (breast), T47D (breast) and MCF-7 (breast), A549 (lung) and HT-29 (colorectal). Compounds 2c and 2d emerged as better anticancer molecules with no toxicity towards normal cells. 2c and 2d inhibited EGFR enzymatic activity in vitro with IC50 values of 617.33 ± 0.04 nM and 710 ± 0.05 nM, respectively. In order to further improve the potency, we explored an unoccupied area of the ATP binding domain of EGFR and analysed an in silico interaction model of 2c and 2d –EGFR complexes that guided and allowed substitution of the 4-fluorophenyl ring (2c and 2d ) with 4-(4-methylpiperazinyl)-3-nitrophenyl at the N-9 position, resulting in compound 3c with a better binding score and potent EGFR inhibitory activity (IC50 : 236.38 ± 0.04 nM), which was comparable to the positive control erlotinib (239.91 ± 0.05 nM). 3c exhibited a great improvement in anticancer potency with inhibition of cell growth of all cancer cell lines at very low micromolar concentrations (IC50 = 1.98 to 4.07 μM). Further investigation revealed that 3c also induced an increase in ROS levels in cancer cells in a mitochondrial-independent manner and halted the cell cycle at the sub-G1 phase.